Insulet Co. (NASDAQ:PODD) Shares Sold by APG Asset Management US Inc.

APG Asset Management US Inc. lessened its stake in Insulet Co. (NASDAQ:PODD) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,449 shares of the medical instruments supplier’s stock after selling 177 shares during the quarter. APG Asset Management US Inc.’s holdings in Insulet were worth $378,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet during the 4th quarter valued at $36,000. SRS Capital Advisors Inc. lifted its holdings in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in shares of Insulet during the 4th quarter valued at $57,000. TD Private Client Wealth LLC lifted its holdings in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares in the last quarter.

Analysts Set New Price Targets

PODD has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Royal Bank of Canada initiated coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target on the stock. TD Cowen lifted their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Canaccord Genuity Group lifted their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Citigroup lifted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Stock Up 7.2 %

NASDAQ PODD opened at $264.72 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company’s 50 day simple moving average is $267.71 and its 200 day simple moving average is $260.19. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a market capitalization of $18.59 billion, a P/E ratio of 45.72, a PEG ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.